1.
Blood
; 143(22): 2332-2335, 2024 May 30.
Artículo
en Inglés
| MEDLINE
| ID: mdl-38635764
RESUMEN
ABSTRACT: We evaluated the cost-effectiveness of prophylaxis with recombinant von Willebrand factor (rVWF) vs with plasma-derived von Willebrand factor (pdVWF) for patients with severe Von Willebrand disease. We found that rVWF is a cost-saving factor replacement compared with pdVWF across all willingness-to-pay thresholds in the United States.
Asunto(s)
Análisis Costo-Beneficio , Proteínas Recombinantes , Enfermedades de von Willebrand , Factor de von Willebrand , Humanos , Factor de von Willebrand/uso terapéutico , Estados Unidos , Proteínas Recombinantes/uso terapéutico , Proteínas Recombinantes/economía , Enfermedades de von Willebrand/economía , Femenino , Masculino
2.
Am J Hematol
; 98(9): E247-E250, 2023 09.
Artículo
en Inglés
| MEDLINE
| ID: mdl-37401660
RESUMEN
Prophylactic emicizumab is cost-ineffective in adults with moderate or mild hemophilia A without inhibitors at current pricing. The price of prophylactic emicizumab would need to decrease by >35% to become cost-effective in this patient population.
